ORAMED PHARMACEUTICALS INC.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.4M | $2.5M | $641.0K | — | — | — | — | — |
| Cost of Revenue | $-86.0K | $187.0K | $490.0K | — | — | — | — | — |
| Gross Profit | $2.5M | $2.3M | $151.0K | — | — | — | — | — |
| Gross Margin | 103.5% | 92.4% | 23.6% | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $12.0M | $10.3M | $7.7M | $4.8M | $3.3M | $-2.3M | $1.7M | $1.2M |
| SG&A Expense | $4.1M | $2.8M | $2.5M | $2.6M | $2.6M | $-2.0M | $1.2M | $1.3M |
| Operating Income | $-13.5M | $-10.8M | $-10.0M | $-7.4M | $-5.9M | $4.3M | $-2.9M | $-2.4M |
| Operating Margin | -552.3% | -438.6% | -1,561.6% | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-12.7M | $-10.1M | $-9.6M | $-7.2M | $-5.7M | $4.4M | $-3.3M | $-1.6M |
| Income Tax Expense | — | $400.0K | $1.3M | $-1.0K | $4.0K | $205.0K | $90.0K | $-24.0K |
| Net Income | $-12.7M | $-10.5M | $-11.0M | $-7.2M | $-5.7M | $4.2M | $-3.3M | $-1.6M |
| Net Margin | -519.7% | -426.7% | -1,710.5% | — | — | — | — | — |
| EPS (Basic) | $0.86 | $0.79 | $0.87 | $0.67 | $0.62 | $0.59 | $0.57 | $-0.02 |
| EPS (Diluted) | $0.86 | $0.79 | $0.87 | $0.67 | $0.62 | $0.59 | $0.57 | $-0.02 |
| Shares Outstanding (Basic) | 17.4M | 14.3M | 13.3M | 11.6M | 10.1M | 7.9M | 86.5M | 70.1M |
| Shares Outstanding (Diluted) | 17.4M | 14.3M | 13.3M | 11.6M | 10.1M | 7.9M | 86.5M | 70.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |